期刊文献+

miR-93在结肠癌中的表达及其意义 被引量:3

下载PDF
导出
摘要 目的研究miR-93在结肠癌组织中的表达与临床病理特征的关系,并探讨其对结肠癌细胞的增殖及细胞周期的影响。方法收集108例结肠癌患者的癌组织及癌旁组织,应用原位杂交和荧光定量PCR检测结肠癌组织及癌旁组织中miR-93的表达水平,分析miR-93表达与结肠癌临床病理特征之间的关系。采用反义miR-93转染降低结肠癌细胞SW480和LoVo中miR-93的表达,采用MTT比色法检测结肠癌细胞增殖的变化情况,利用流式细胞仪检测结肠癌细胞周期的变化情况。结果原位杂交检测显示,结肠癌组织miR-93阳性表达率高于癌旁组织(P<0.05);荧光定量PCR检测显示,61.11%(66/108)的结肠癌组织miR-93表达明显高于癌旁组织(P<0.05);随着结肠癌临床分期的进展,miR-93的表达量逐渐升高,临床Ⅲ/Ⅳ期、Ⅰ/Ⅱ期结肠癌miR-93的表达与癌旁组织相比都显著增高(P<0.05);有淋巴结转移的结肠癌患者的miR-93的表达比无淋巴结转移者显著增加(P<0.05);反义miR-93转染结肠癌细胞SW480和LoVo后,miR-93的表达明显降低,SW480和LoVo结肠癌细胞生长受到明显抑制,其生长主要停滞在G0/G1期,而S期和G2/M期细胞的比例下降。结论 miR-93与结肠癌的发生发展密切相关,其可以通过调节细胞周期中G1/S期的转换而影响结肠癌细胞的生长,为结肠癌治疗提供新的靶点。
出处 《山东医药》 CAS 2012年第33期51-54,共4页 Shandong Medical Journal
  • 相关文献

参考文献9

  • 1Zeng Y. Principles of micro-RNA production and maturation [ J ]. Oncogene, 2006,25 (46) :6156-6162.
  • 2Croce CM. Causes and consequences of microRNA dysregulation in cancer [J] . Nat Rcv C, enet, 2009,10 ( 10 ) :704-714.
  • 3Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non- tumorous tissues[ J]. Oncogene, 2006,25 ( 17 ) :2537-2545.
  • 4Jiang J, Gusev Y, Aderca I, et al. Association of MicroRNA ex- pression in hepatocellular carcinomas with hepatitis infection, cir- rhosis, and patient survival [ J ]. Clin Cancer Res, 2008,14 ( 2 ) : 419-427.
  • 5Jemal A, Siegel R, Ward E. Cancer statistics, 2007 [ J ]. CA Canc- er J Clin, 2007,57(1) :43-66.
  • 6KrUtzfeldt J, Bajewsky N, Braich B, et 81. Silencing of mieroRNAs in vivo with' antagomirs' [ J ]. Nature, 2005,438 (7068) :685-689.
  • 7Montanini L, Lasagna L, Barili V, et al. MicroRNA cloning and se- quencing in osteosarcoma cell lines: differential role of miR-93 [ J ]. Cell Oncol( Dordr), 2012,35( 1 ) :29-41.
  • 8Du L, Schageman JJ, Subauste MC, et al. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUSI [ J ]. Mol Cancer Res, 2009,7(8) :1234-1243.
  • 9Fang L, Deng Z, Shatseva T, et al. MicmRNA miR-93 promotes tumor growth and angingenesis by targeting integrin-[381[ J ]- Onco- gene, 2011,30(7) :806-821.

同被引文献28

  • 1Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010,60(5) :277-300.
  • 2Verdecchia A, Francisci S, Brenner H, et al. Recent cancer sur- vival in Europe: a 2000--- 02 period analysis of EUROCARE-4 data[ J]. Lancet Oncol, 2007, 8(9) :784-796.
  • 3Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers [ J ]. Brit J Cancer, 2010, 102(7): 1174-1179.
  • 4Li BS, Zhao YL, Guo G, et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection [ J/OL]. PLoS One, 2012, 7 (7) [ 2014-08- 08]. http ://www. ncbi. nlm. nih. gov/pmc/articles/PMC3408505.
  • 5Zhu W, He J, Chen D, et al. Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer[J/OL]. PLoS One, 2014, 9(2) [2014-08- 01 ]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921142.
  • 6Murata K, Yoshitomi H, Tanida S, et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and asteoarthritis[ J ]. Arthritis Res Ther, 2010, 12(3) : 86.
  • 7O'Connell RM, Rao DS, Chaudhuri AA, et al. Physiological and pathological roles for microRNAs in the immune system [ J ]. Nat Rev Immunol, 2010, 10(2) :111-122.
  • 8Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis[J]. Mol Carcinog, 2011, 50(2): 136-142.
  • 9Li X, Zhang Y, Zhang H, et al. microRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3[J]. Mol Cancer Res, 2011, 9(7) : 824-833.
  • 10McDonald MK, Capasso KE, Ajit SK. Purification and microRNA profiling of exosomes derived from blood and culture media[J]. J Vis Exp, 2013, 14(76) :e50294.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部